Syndax Announces Participation in March Investor Conferences
Rhea-AI Summary
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare. CEO Michael A. Metzger will take part in fireside chats on March 2, 11, and 12, 2026.
A live webcast and limited-time replay will be available in the company’s Investor section at www.syndax.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SNDX fell 4.56% while close peers showed mixed moves: ARDX -11.71%, VRDN -2.66%, BHVN +0.36%, VERA roughly flat. No broad, aligned sector move is evident.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings call date | Neutral | +1.6% | Announced Q4 and full-year 2025 results date and investor call details. |
| Feb 05 | Conference participation | Neutral | -1.4% | CEO fireside chat at Guggenheim Emerging Outlook: Biotech Summit with webcast. |
| Feb 04 | Inducement equity grants | Negative | -3.9% | Announced 11,600-share option grants to new employees under inducement plan. |
| Jan 12 | Prelim 2025 results | Positive | -1.3% | Reported strong preliminary Revuforj and Niktimvo revenues and cash position. |
| Jan 07 | Access program launch | Positive | +8.7% | Launched multi-regional Revuforj managed access program outside the U.S. |
News flow has been frequent, with generally mild price responses; one positive access/expansion update saw the strongest upside reaction.
Over the past two months, Syndax has issued several operational and investor‑relations updates. These include an earnings call announcement on Feb 26, 2026, multiple conference participation notices, inducement equity grants, preliminary 2025 revenue and cash figures highlighted on Jan 12, 2026, and a multi‑regional Revuforj access program announced on Jan 7, 2026. Price reactions were usually modest, except for the Revuforj access news, which produced an 8.7% gain, indicating strongest enthusiasm for concrete commercial or access milestones.
Market Pulse Summary
This announcement outlines upcoming fireside chats at three March healthcare conferences, signaling continued investor‑relations engagement rather than new clinical or financial data. In recent months, Syndax updates ranged from preliminary 2025 revenues to expanded Revuforj access, with the latter driving an 8.7% move. Investors may focus more on future concrete milestones—trial progress, revenue updates, or additional access initiatives—than on conference logistics or webcast availability.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- TD Cowen 46th Annual Health Care Conference in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET.
- Leerink Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Wednesday, March 11, 2026, at 1:40 p.m. ET.
- Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 12, 2026, at 11:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When will Syndax (SNDX) present at the TD Cowen Health Care Conference in March 2026?
How can investors watch Syndax (SNDX) fireside chats at the March 2026 conferences?
Which Syndax (SNDX) executives will appear at the March 2026 Leerink and Barclays conferences?
What are the scheduled times for Syndax (SNDX) at the March 11 and March 12, 2026 conferences?
Where will the March 2026 Syndax (SNDX) investor conferences take place and which events are they?
